Rates of liver retransplantation in the United States are declining in the era of direct-acting antiviral agents

被引：3
|
作者：
Cholankeril, G. [1 ]
Yoo, E. R. [2 ]
Hu, M. [3 ]
Gadiparthi, C. [1 ]
Khan, M. A. [1 ]
Perumpail, R. B. [4 ]
Bonham, C. A. [5 ]
Ahmed, A. [4 ]
机构：
[1] Univ Tennessee, Ctr Hlth Sci, Div Gastroenterol & Hepatol, Memphis, TN 38163 USA
[2] Univ Illinois, Coll Med, Dept Med, Chicago, IL USA
[3] Brown Univ, Sch Publ Hlth, Dept Biostat, Providence, RI 02912 USA
[4] Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA
[5] Stanford Univ, Sch Med, Dept Surg, Div Abdominal Transplantat, Stanford, CA 94305 USA
来源：
JOURNAL OF VIRAL HEPATITIS | 2017年 / 24卷 / 12期
关键词：
direct-acting antiviral; hepatitis C virus; liver transplantation; retransplantation; HEPATITIS-C; INFECTION;
D O I：
10.1111/jvh.12750
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：1194 / 1195
页数：2
相关论文
共 50 条
  • [1] Equivalent Outcomes With Retransplantation and Primary Liver Transplantation in the Direct-acting Antiviral Era
    Croome, Kristopher P.
    Mathur, Amit K.
    Pungpapong, Surakit
    Lee, David D.
    Moss, Adyr A.
    Rosen, Charles B.
    Heimbach, Julie K.
    Taner, C. Burcin
    TRANSPLANTATION, 2019, 103 (06) : 1168 - 1174
  • [2] Liver transplantation for hepatitis C virus in the era of direct-acting antiviral agents
    Audrey, Coilly
    Raffaele, Bruno
    CURRENT OPINION IN HIV AND AIDS, 2015, 10 (05) : 361 - 368
  • [3] Retransplantation outcomes for hepatitis C in the United States before and after direct-acting antiviral introduction
    Ivanics, Tommy
    Rizzari, Michael
    Moonka, Dilip
    Al-Kurd, Abbas
    Delvecchio, Khortnal
    Kitajima, Toshihiro
    Elsabbagh, Ahmed M.
    Collins, Kelly
    Yoshida, Atsushi
    Abouljoud, Marwan
    Nagai, Shunji
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (03) : 1100 - 1112
  • [4] IMPACT OF DIRECT-ACTING ANTIVIRAL AGENTS ON LIVER TRANSPLANT OUTCOMES AMONG BLACK RECIPIENTS IN THE UNITED STATES
    Ochoa-Allemant, Pedro
    Ezaz, Ghideon
    HEPATOLOGY, 2021, 74 : 915A - 915A
  • [5] LIVER TRANSPLANTATION IN THE UNITED STATES IN THE DIRECT-ACTING ANTIVIRAL ERA: PROFOUND CHANGES IN INDICATIONS, DEMOGRAPHICS, AND PRETRANSPLANT COMORBIDITIES
    Faust, Nolan W.
    Cotter, Thomas
    Sandikci, Burhaneddin
    Paul, Sonali
    di Sabato, Diego
    Little, Ester C.
    Vinay, Sundaram
    Fung, John
    Charlton, Michael
    GASTROENTEROLOGY, 2020, 158 (06) : S1265 - S1265
  • [6] Treating paediatric hepatitis C in the era of direct-acting antiviral agents
    Alqahtani, Saleh A.
    Colombo, Massimo G.
    LIVER INTERNATIONAL, 2021, 41 (06) : 1189 - 1200
  • [7] Complexities of HCV management in the new era of direct-acting antiviral agents
    Rosenberg, W. M.
    Tanwar, S.
    Trembling, P.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2014, 107 (01) : 17 - 19
  • [8] Rheumatologic manifestations of hepatitis C in the era of direct-acting antiviral agents
    Priora, Marta
    Realmuto, Cristina
    Parisi, Simone
    Ditto, Maria C.
    Borrelli, Richard
    Peroni, Clara L.
    Lagana, Angela
    Fusaro, Enrico
    MINERVA GASTROENTEROLOGICA E DIETOLOGICA, 2020, 66 (03) : 280 - 289
  • [9] Microbiota and hepatitis C virus in the era of direct-acting antiviral agents
    Pinchera, Biagio
    Moriello, Nicola Schiano
    Buonomo, Antonio Riccardo
    Zappulo, Emanuela
    Viceconte, Giulio
    Villari, Riccardo
    Gentile, Ivan
    MICROBIAL PATHOGENESIS, 2023, 175
  • [10] Maximizing access to HCV treatment with direct-acting antiviral agents for uninsured patients in the United States
    Carrion, Andres F.
    Flores, Melissa
    Martinez, Jose L. Gonzalez
    Romero, Roberta
    Zuckerman, Marc J.
    HEPATOLOGY, 2016, 64 : 978A - 978A
12345